Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 25 April 2026
2025-09-16 09:27:00 Tuesday ET

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fund
2019-07-15 16:37:00 Monday ET

President of US-China Business Council Craig Allen states that a trade deal should be within reach if Trump and Xi show courage at G20. A landmark trade agr
2018-12-21 11:39:00 Friday ET

The Internet and telecom conglomerate SoftBank Group raises $23 billion in the biggest IPO in Japan. Going public is part of the major corporate move away f
2018-05-02 06:32:00 Wednesday ET

What are the primary pros and cons of free trade or fair trade in the current Sino-American quagmire? Free trade means allowing goods and services to move a
2017-12-17 11:41:00 Sunday ET

Warren Buffett points out that it is important to invest in oneself. Learning about oneself empowers him or her to lead a meaningful life. This valuable inv
2019-03-31 11:40:00 Sunday ET

AYA Analytica free finbuzz podcast channel on YouTube March 2019 In this podcast, we discuss several topical issues as of March 2019: (1) Sargent-Wallac